1 day Ago By ABMN Staff
Arcellx, Inc. ( NASDAQ:ACLX – Get Free Report ) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 3,930,000 shares, a decline of 5.
8% from the October 15th total of 4,170,000 shares. Based on an average trading volume of 520,900 shares, the short-interest ratio is presently 7.5 days.
Approximately 9.7% of the shares of the stock are sold short. Arcellx Stock Performance Shares of ACLX stock opened at $87.
59 on Wednesday. Arcellx has a one year low of $46.42 and a one year high of $107.
37. The firm’s 50 day moving average price is $86.52 and its 200-day moving average price is $68.
25. The firm has a market cap of $4.74 billion, a P/E ratio of -123.
36 and a beta of 0.27. Arcellx ( NASDAQ:ACLX – Get Free Report ) last released its quarterly earnings data on Thursday, November 7th.
The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.
06. The business had revenue of $26.03 million for the quarter, compared to the consensus estimate of $35.
21 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.
94%. As a group, research analysts predict that Arcellx will post -1.49 EPS for the current fiscal year.
Wall Street Analyst Weigh In Check Out Our Latest Analysis on ACLX Insider Buying and Selling In other news, insider Christopher Heery sold 27,451 shares of Arcellx stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $67.03, for a total transaction of $1,840,040.
53. Following the completion of the transaction, the insider now directly owns 9,278 shares in the company, valued at $621,904.34.
This trade represents a 74.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink .
Also, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $74.41, for a total transaction of $111,615.
00. The disclosure for this sale can be found here . Insiders have sold 119,557 shares of company stock worth $10,163,933 in the last 90 days.
Insiders own 6.24% of the company’s stock. Institutional Investors Weigh In On Arcellx A number of hedge funds and other institutional investors have recently bought and sold shares of ACLX.
Quest Partners LLC acquired a new stake in shares of Arcellx during the second quarter valued at $27,000. Plato Investment Management Ltd acquired a new stake in shares of Arcellx during the first quarter valued at about $51,000. Decheng Capital LLC purchased a new stake in Arcellx during the 2nd quarter worth approximately $65,000.
National Bank of Canada FI raised its holdings in Arcellx by 50.0% in the second quarter. National Bank of Canada FI now owns 1,500 shares of the company’s stock valued at $80,000 after acquiring an additional 500 shares in the last quarter.
Finally, Quarry LP acquired a new stake in shares of Arcellx in the 3rd quarter valued at about $125,000. Institutional investors and hedge funds own 96.03% of the company’s stock.
Arcellx Company Profile ( Get Free Report ) Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). Recommended Stories Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.
com's FREE daily email newsletter ..
